Targeted IL-1 Leverage MB-IL1RA to position ProteoThera as a candidate for high-value autoinflammatory indications such as acute gout, offering a localized therapy approach that could differentiate from systemic IL-1 inhibitors and expand access to patients in need.

Localized Delivery Advantage Promote the MB platform as enabling localized or subcutaneous delivery of existing therapeutics, creating potential co-development or licensing deals with established drug developers seeking improved safety profiles and reduced systemic exposure.

De-risked FDA Path Emphasize the strategy of utilizing previously validated or approved therapies with ProteoThera’s MB technology to shorten regulatory timelines and reduce development risk, appealing to big pharma partners seeking faster time-to-market.

Early Stage Partnering Target collaborations with large pharmaceutical companies looking to extend portfolios in autoinflammation and tissue regeneration, offering a modular platform that can retrofit existing drugs for localized action.

Funding & Growth Signals Position as an early-stage biotech with a potentially scalable value proposition; despite modest revenue, pursue strategic partnerships and milestone-driven deals to validate platform viability and unlock larger collaboration opportunities.